Sydney Jennings is an Editor at Patient Care Online. She specializes in various aspects of medicine and healthcare, including aging and longevity, diet and nutrition, mental health, and healthcare technology. Sydney's work has been featured in Patient Care, where she brings attention to critical health news and wellness topics.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Sydney's coverage primarily focuses on healthcare, pharmaceuticals, and scientific research. She frequently incorporates data into her articles, and her topics encompass cardiovascular health, medication risks, primary prevention, obesity, hypertension, liver disease (including hepatic encephalopathy), and various research studies.
Given the nature of Sydney's articles heavily relying on cited data and expert commentary to support claims or findings in the field of healthcare and pharmaceuticals would be beneficial. Experts who can provide insights into new research studies related to cardiovascular health or medication risks could be valuable sources for her articles.
As there is no specified geographic focus for Sydney Jennings' work; experts from any location with relevant expertise may find value in reaching out to offer their insights.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Catch up on the 7 FDA drug approvals most relevant to primary care, including new options for hypertension, weight management, acne, and more.
By: Sydney Jennings
AI-generated portal message drafts often missed clinical context and required physician editing in a Dartmouth analysis.
By: Sydney Jennings
Once-weekly subcutaneous lecanemab matched IV initiation exposure in early Alzheimer disease, but comparative clinical outcome data remain limited.
By: Sydney Jennings
A new analysis estimates the 2026 dyslipidemia guideline expands primary prevention statin eligibility to 87.5 million US adults.
Recent FDA actions include approvals and clearances in lipid management, CRC screening, contraception, vaginitis testing, and Alzheimer psychosis.
By: Sydney Jennings
A McGill University–led team developed a prediction model integrating pregnancy-related factors to identify cardiovascular disease risk in women aged 15 to 45.
By: Abigail Brooks
The organizations challenge a presidential executive order narrowing routine childhood vaccine recommendations and urging vaccines to be given separately.
By: Abigail Brooks
Insulin icodec is now available in the US after FDA approval, offering adults with type 2 diabetes a once-weekly basal insulin option.
By: Abigail Brooks
Phase 3 LUCIDITY results showed avexitide reduced Level 2 and Level 3 hypoglycemic events by 55% vs placebo in post-bariatric hypoglycemia.
By: Abigail Brooks
FDA approved garetosmab for adults with FOP after phase 3 data showed fewer new HO lesions and clinician-assessed flare-ups vs placebo.
